Trials / Completed
CompletedNCT01910506
RDEA3170 AME Study
A Phase 1 Absorption, Metabolism and Excretion Study of [14C]RDEA3170 Orally Administered to Healthy Adult Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Ardea Biosciences, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will determine the characteristics of absorption, metabolism, and excretion (AME) of RDEA3170 following a single 10 mg dose of RDEA3170 oral solution with 500 microcuries (µCi) of \[14 C\]RDEA3170 in healthy adult male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDEA3170 10 mg |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2013-09-01
- Completion
- 2013-11-01
- First posted
- 2013-07-29
- Last updated
- 2014-01-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01910506. Inclusion in this directory is not an endorsement.